Actively Recruiting
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Led by Duke University · Updated on 2026-04-21
80
Participants Needed
4
Research Sites
197 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is to study if neoadjuvant atezolizumab therapy is beneficial for patients with recurrent glioblastoma and a low mutational burden.
CONDITIONS
Official Title
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Pathologically confirmed glioblastoma, IDH wild type
- Clinical or radiological evidence of first or second recurrence after radiation and temozolomide treatment
- Tissue sample available from initial diagnosis of primary glioblastoma
- Adequate organ function including hemoglobin ≥ 9 g/dl, platelet count ≥ 75,000/µl, neutrophil count ≥ 1000 cells/mm3, creatinine ≤ 1.5 times upper limit of normal, total bilirubin ≤ 1.5 times upper limit of normal (or ≤ 3.0 if Gilbert's Syndrome), alkaline phosphatase ≤ 2.5 times upper limit of normal, AST and ALT ≤ 2.5 times upper limit of normal, serum albumin ≥ 25 g/L, and normal prothrombin and partial thromboplastin times
- Karnofsky Performance Status score of 70% or higher
- Patient or partner meets criteria for non-childbearing potential or agrees to use approved birth control methods
- Signed informed consent approved by Institutional Review Board
- Negative HIV test or stable HIV on therapy with adequate CD4 count and undetectable viral load
- Negative hepatitis B surface antigen and core antibody tests, or negative HBV DNA if indicated
- Negative hepatitis C antibody test or negative HCV RNA if indicated
You will not qualify if you...
- Pregnancy, breastfeeding, or intention to become pregnant during treatment or within 5 months after final dose
- Prior treatment with immunotherapy
- Treatment with bevacizumab within 4 weeks before biopsy (with exceptions for certain uses)
- Use of systemic immunosuppressive medication above specified thresholds within 2 weeks before treatment
- History of severe allergic reactions to antibodies or fusion proteins
- Hypersensitivity to Chinese hamster ovary cell products or atezolizumab components
- Active autoimmune disease or immune deficiency except specific controlled conditions
- Less than 12 weeks from radiation therapy without progressive disease or two progressive MRIs
- Contraindications to surgery
- Significant cardiovascular disease within 3 months prior to treatment
- Major surgery within 4 weeks prior to treatment
- Recent history of malignancy with exceptions for low-risk cancers
- Severe infection within 4 weeks prior to treatment
- Treatment with live vaccines within 4 weeks prior or during treatment
- Treatment with investigational therapy within 28 days prior to treatment
- Prior treatment with CD137 agonists or immune checkpoint blockades
- Uncontrolled pleural, pericardial effusion, or ascites requiring frequent drainage
- Uncontrolled or symptomatic hypercalcemia
- Active tuberculosis
- History or evidence of certain pulmonary diseases or pneumonitis
- Treatment with therapeutic antibiotics within 2 weeks prior to treatment
- Prior allogeneic stem cell or solid organ transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
2
Saint Luke's Cancer Institute
Kansas City, Missouri, United States, 64111
Active, Not Recruiting
3
Duke University
Durham, North Carolina, United States, 27705
Actively Recruiting
4
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Actively Recruiting
Research Team
M
Mustafa Khasraw, MD
CONTACT
M
Monika Anand, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here